Changes in FDG uptake after subsequent cycles of neoadjuvant therapy can predict long-term patient survival. Researchers from the Technical University of Munich reported these findings at the Society of Nuclear Medicine meeting in June.
Changes in FDG uptake after subsequent cycles of neoadjuvant therapy can predict long-term patient survival. Researchers from the Technical University of Munich reported these findings at the Society of Nuclear Medicine meeting in June.
Dr. Stefanie Sassen and colleagues enrolled 33 patients who underwent FDG-PET imaging of the abdomen and pelvis before and after carboplatin-based chemotherapy. Patients went on to debulking surgery after chemo and were monitored for three years.
The researchers observed a significant correlation between FDG-PET uptake changes and patient survival after the first and third cycles of therapy. Overall survival of patients classified as responders and nonresponders to FDG-PET was 38.9 months and 19.7 months, respectively.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.